Identification

Numero CAS

42924-53-8

Nom scientifique (FR)

Nabumétone

Nom scientifique (EN)

4-(6-methoxynaphthalen-2-yl)butan-2-one

Autres dénominations scientifiques (Autre langues)

nabumetone ; 4-(6-methoxynaphthalen-2-yl)butan-2-on ; 4-(6-methoxynaphthalen-2-yl)butan-2-one ; 4-(6-methoxy-2-naphthyl)-butan-2-one ; wassermann brand of nabumetone ; uriach brand of nabumetone ; smithkline brand of nabumetone ; smithkline beecham brand of nabumetone ; rhoxalpharma brand of nabumetone ; rhoxal-nabumetone ; mayoly-spindler brand of nabumetone ; glaxosmithkline brand of nabumetone ; genpharm brand of nabumetone ; gen-nabumetone ; apotex brand of nabumetone ; apo-nabumetone ; nabumetone-d3 ; 1h-imidazole, 2-ethyl-5-methyl- ; 2-butanone, 4-(6-methoxy-2-naphthalenyl)- ; 4-(6-methoxy-2-naphthyl)-2-butanone ; relafen ; relifex ; nabumeton ; nabumetona ; nabum??tone ; nabumetone ; nabumetonum ; 4-(6-methoxy-2-naphthalenyl)-2-butanone ; relafen (tn) ; relif ; prodac ; nabuser ; mebutan ; unimetone ; flambate ; dolsinal ; relifex ; relifen ; listran ; relafen ; 4-(6-methoxy-naphthalen-2-yl)-butan-2-one ; nabucox ; arthraxan ; nabumeton ; nabumeton ; nabumetona ; nabumetonum ; arthaxan ; balmox ; dolsinal ; listran ; mebutan ; nabuser ; relafen ; relif ; relifen ; relifex ; nabumetone (jan/usp/inn) ; idi1_000850 ; bspbio_000758 ; bpbio1_000834 ; relifen (trade name) ; relif (trade name) ; relafen (trade name) ; nabuser (trade name) ; mebutan (trade name) ; listran (trade name) ; dolsinal (trade name) ; nabumetonum ; nabumetona ; 1-(2'-methoxynaphth-6'-yl)butan-3-one ; arthaxan, relafen ; 4-(2-methoxynaphthalen-6-yl)butan-2-one ; 2103472

Code EC

-

Code SANDRE

-

Number CIPAC

-

Formule chimique brute

\(\ce{ C15H16O2 }\)

Code InChlKey

BLXXJMDCKKHMKV-UHFFFAOYSA-N

Code SMILES

COc1ccc2cc(CCC(C)=O)ccc2c1

Accidental values

Other accidental thresholds

Other accidental thresholds
ineris name Duration Value Source Status state Commentary
PAC-1 60 min 1,5 mg.m-3 EHSS (2018) Final
TEEL-2/11, human oral TDLo, monkey oral LD50
PAC-2 60 min 16 mg.m-3 EHSS (2018) Final
TEEL-2/11, human oral TDLo, monkey oral LD50
PAC-3 60 min 620 mg.m-3 EHSS (2018) Final
TEEL-2/11, human oral TDLo, monkey oral LD50
This is a preview

This table has too many entries to display it completely. For a full display, use one of the options above.

Bibliography